Retension Pharma director Franklin M. Berger acquires 10,000 common shares for $120,000
Retension Pharmaceuticals director Franklin M. Berger increased exposure to the stock via conversion into 12,517 common shares. Separate purchase added 10,000 common shares at $12, held indirectly through FMB Research. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial int